Cancer BiologyNature CommunicationsPeer-reviewed
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy
Jana Samarin, Hana Nůsková, Piotr Fabrowski…·Nikolas Gunkel
The paper shows that activating the NRF2 pathway can safely increase the dose of TXNRD1 inhibitors in SCLC treatment without harming healthy tissues.
4 citationstop 3%